Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-dysplastic myelodysplasia?

P G Cachia1, C Taylor, P W Thompson

  • 1Leukemia Research Fund Preleukemia Unit, Hematology Department, University of Wales College of Medicine, Cardiff, UK.

Leukemia
|April 1, 1994
PubMed
Summary

Patients treated for cancer with chemotherapy may develop myelodysplasia (MDS) and acute myeloid leukemia (AML). This study details a Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seventy ova.

The Hastings Center report·2003
Same author

FMRP expression studies in blood and hair roots in a fragile X family with methylation mosaics.

Journal of medical genetics·2003
Same author

Predictive testing for cognitive functioning in female carriers of the fragile X syndrome using hair root analysis.

Journal of medical genetics·2003
Same author

Intraoperative MRI and adjuvant radiosurgery.

Stereotactic and functional neurosurgery·2002
Same author

A high-performance liquid chromatography/tandem mass spectrometric screening method for eight synthetic corticosteroids in bovine feces and the simultaneous differentiation between dexamethasone and betamethasone.

Rapid communications in mass spectrometry : RCM·2002
Same author

Neuro-cognitive and behavioural aspects in non-specific mental retardation. A proposal for phenotyping new XLMR genes.

Genetic counseling (Geneva, Switzerland)·2002

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Cytotoxic therapy for malignancies like Hodgkin's disease (HD) increases the risk of secondary myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
  • Long-term survivors of cancer treatment require monitoring for treatment-related hematologic complications.

Observation:

  • A patient in remission from HD after combination chemotherapy presented with biological and genetic abnormalities indicative of MDS.
  • X-inactivation analysis showed polyclonal hematopoiesis, but cytogenetics revealed a clonal population with a 7q-deletion.
  • NRAS mutations (codons 12 and 15) emerged 4 years post-treatment, confirmed by sequencing and tumorigenicity assays.
  • In vitro studies showed decreased granulocyte-macrophage colony-forming units (CFU-GM) and reduced erythroid burst-forming units (BFU-E).

Related Experiment Videos

Findings:

  • The patient exhibited clonal genetic abnormalities (7q-deletion, NRAS mutations) and functional hematopoietic stem cell defects characteristic of MDS, despite a normal hematologic profile.
  • The emergence of NRAS mutations in distinct clones suggests a complex clonal evolution process.
  • Functional assays demonstrated significant impairment in myeloid and erythroid progenitor growth.

Implications:

  • These findings highlight the potential for subclinical MDS development following cytotoxic therapy.
  • Early detection of genetic and biological abnormalities may precede overt clinical MDS, enabling closer patient monitoring.
  • Understanding clonal evolution in therapy-related MDS is crucial for predicting disease progression and developing targeted interventions.